Dan Elbaum
Chief Scientific Officer QurAlis Corp.
Seminars
Thursday 24th September 2026
Stabilizing Neuronal Hyperexcitability to Advance Clinically Translatable Kv7 Therapies for ALS
1:30 pm
- Targeting selective Kv7.2/7.3 activation to reduce motor neuron hyperexcitability associated with ALS progression
- Applying electrophysiology and translational biomarkers to improve confidence in CNS ion channel clinical development
- Demonstrating how improved selectivity and brain penetration can support safer chronic dosing in neurodegenerative disease
